Aspire Biopharma appoints Phillip Balatsos to board of directors

Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) announced the appointment of Phillip Balatsos to its board of directors, effective February 6. The appointment follows the planned departures of Suren Ajjarapu and Donald G. Fell from the board.

Balatsos brings over 25 years of experience in financial markets, including roles at Barclays Capital, Credit Suisse, and XP Investments. He currently operates within an independent trading platform at Oscar Gruss & Son. His background spans foreign exchange, emerging markets, institutional sales and trading, and public company governance.

The new director also has entrepreneurial experience, having founded and scaled a multi-location hospitality business and advised national restaurant groups on procurement, pricing, and operational efficiency.

Balatsos currently serves on the boards of Inspire Veterinary Partners, Inc., where he is a member of the audit committee, and Ciso Global, Inc., a cybersecurity and risk management company. He previously served on the board of Sadot Group Inc., participating in both the audit and executive compensation committees.

At Aspire Biopharma, Balatsos will serve on the audit and compensation committees. He holds a Bachelor of Science in Business Administration from Skidmore College.

"The Company's mission to provide rapid-onset therapeutics through novel sublingual formulations resonates strongly with my experience in scaling growth-stage companies," Balatsos said in a statement.

Aspire Biopharma develops patent-pending sublingual delivery technology designed to deliver drugs rapidly and precisely to the bloodstream while avoiding the gastrointestinal tract. The technology can be applied to various active pharmaceutical ingredients and bioactive substances.

You May Also Be Interested In

• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• Baxter raises tender offer cap to $600M for senior notes
• Jaguar Uranium reports copper assay results at Argentina project